ALL
FDA Grants Accelerated Approval to Iclusig With Chemotherapy for Newly Diagnosed Ph-positive ALL
The FDA granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A.) with chemotherapy for ...
MARCH 19, 2024
Measurable Residual Disease Testing in the Community Oncology Setting
In the game of chess, anticipating the correct response to each of your opponent’s moves on the board can ...
FEBRUARY 7, 2024
BiTE Therapy Shows Promise in R/R ALL
Although only a phase 1b dose-finding study in patients with relapsed/refractory (R/R) B-cell precursor acute ...
MARCH 16, 2022
Studies Point to Optimal Dosing in Acute Leukemia and Lymphoma
Two new studies of drugs already licensed for cancer—one indicated for acute lymphoblastic leukemia and one ...
JANUARY 20, 2022
Real-World Study Adds Insight on CART-19 Therapy Safety
BARCELONA—The real-world safety of CART-19 treatment is similar to adverse event rates documented in clinical ...
OCTOBER 24, 2019
